Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.47%KO-0.71%0700.HK-6.35%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.84%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.70%0857.HK-2.43%UNH-10.21%1288.HK-1.71%PM-0.85%0005.HK-2.16%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.69%AUDUSD-1.59%EURAUD+1.01%AUDCAD-1.00%AUDCHF-1.00%GBPAUD+0.95%AUDNZD-0.95%NZDJPY-0.77%GBPJPY-0.75%EURJPY-0.72%CADJPY-0.70%CHFJPY-0.70%AUDSGD-0.64%NZDUSD-0.64%GBPUSD-0.62%USDCHF+0.62%USDCAD+0.60%EURUSD-0.59%AUDDKK-0.57%USDZAR+0.48%GBPTRY+0.41%AUDNOK-0.40%USDMXN+0.39%NZDMXN+0.35%USDTHB+0.32%GBPHKD+0.32%EURZAR+0.32%USDNOK+0.31%GBPZAR+0.30%GBPMXN-0.28%CHFNOK+0.24%NOKJPY-0.23%USDSEK+0.22%USDTRY+0.21%USDPLN+0.20%EURCNH-0.18%EURNOK+0.16%EURHKD-0.16%USDILS+0.16%CHFSEK+0.15%USDDKK+0.15%USDJPY-0.13%USDCNH-0.12%PLNJPY-0.10%GBPSGD-0.09%EURSGD-0.08%EURSEK+0.08%USDSGD+0.07%NZDCAD-0.07%EURPLN+0.05%NZDCHF-0.05%GBPCAD-0.05%EURNZD+0.05%EURGBP+0.05%NZDSGD+0.04%USDCOP-0.04%EURCZK+0.04%SGDJPY+0.03%EURCHF+0.03%CADCHF+0.02%USDHKD-0.02%GBPNZD+0.02%GBPCHF-0.01%CHFSGD-0.01%EURCAD0.00%EURDKK0.00%XPTUSD-1.03%XAGUSD-0.70%GAGUSD-0.70%HG1-0.63%W1-0.55%GAUUSD-0.52%XAUUSD-0.52%XNGUSD-0.42%C1-0.40%S1-0.18%UKOIL+0.17%USOIL-0.12%BTCUSD-3.42%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.76%XMRUSDT-2.10%DOGEUSD+55.95%LINKUSD-3.24%XLMUSD-3.75%BCHUSDT-3.45%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.88%TONUSD+59.18%HBARUSDT-5.17%TAOUSDT-3.05%AAVEUSD-3.31%ONDOUSDT-5.19%ICPUSDT-2.22%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.51%ATOMUSDT-2.31%INJUSDT-7.34%STXUSDT-3.10%PYTHUSDT-0.66%TIAUSDT-3.10%FETUSDT-4.54%JUPUSDT-0.13%SEIUSDT-4.48%GRTUSDT-3.25%OPUSDT-3.90%IOTAUSDT-2.39%POLUSDT-1.98%WIFUSDT-2.98%AXSUSDT-2.76%EOSUSDT-4.24%IMXUSDT-3.36%FARTCOINUSDT-6.86%GALAUSDT-2.38%DYDXUSDT-2.73%ORDIUSDT-2.46%NOTUSDT-2.34%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.47%KO-0.71%0700.HK-6.35%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.84%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.70%0857.HK-2.43%UNH-10.21%1288.HK-1.71%PM-0.85%0005.HK-2.16%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.69%AUDUSD-1.59%EURAUD+1.01%AUDCAD-1.00%AUDCHF-1.00%GBPAUD+0.95%AUDNZD-0.95%NZDJPY-0.77%GBPJPY-0.75%EURJPY-0.72%CADJPY-0.70%CHFJPY-0.70%AUDSGD-0.64%NZDUSD-0.64%GBPUSD-0.62%USDCHF+0.62%USDCAD+0.60%EURUSD-0.59%AUDDKK-0.57%USDZAR+0.48%GBPTRY+0.41%AUDNOK-0.40%USDMXN+0.39%NZDMXN+0.35%USDTHB+0.32%GBPHKD+0.32%EURZAR+0.32%USDNOK+0.31%GBPZAR+0.30%GBPMXN-0.28%CHFNOK+0.24%NOKJPY-0.23%USDSEK+0.22%USDTRY+0.21%USDPLN+0.20%EURCNH-0.18%EURNOK+0.16%EURHKD-0.16%USDILS+0.16%CHFSEK+0.15%USDDKK+0.15%USDJPY-0.13%USDCNH-0.12%PLNJPY-0.10%GBPSGD-0.09%EURSGD-0.08%EURSEK+0.08%USDSGD+0.07%NZDCAD-0.07%EURPLN+0.05%NZDCHF-0.05%GBPCAD-0.05%EURNZD+0.05%EURGBP+0.05%NZDSGD+0.04%USDCOP-0.04%EURCZK+0.04%SGDJPY+0.03%EURCHF+0.03%CADCHF+0.02%USDHKD-0.02%GBPNZD+0.02%GBPCHF-0.01%CHFSGD-0.01%EURCAD0.00%EURDKK0.00%XPTUSD-1.03%XAGUSD-0.70%GAGUSD-0.70%HG1-0.63%W1-0.55%GAUUSD-0.52%XAUUSD-0.52%XNGUSD-0.42%C1-0.40%S1-0.18%UKOIL+0.17%USOIL-0.12%BTCUSD-3.42%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.76%XMRUSDT-2.10%DOGEUSD+55.95%LINKUSD-3.24%XLMUSD-3.75%BCHUSDT-3.45%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.88%TONUSD+59.18%HBARUSDT-5.17%TAOUSDT-3.05%AAVEUSD-3.31%ONDOUSDT-5.19%ICPUSDT-2.22%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.51%ATOMUSDT-2.31%INJUSDT-7.34%STXUSDT-3.10%PYTHUSDT-0.66%TIAUSDT-3.10%FETUSDT-4.54%JUPUSDT-0.13%SEIUSDT-4.48%GRTUSDT-3.25%OPUSDT-3.90%IOTAUSDT-2.39%POLUSDT-1.98%WIFUSDT-2.98%AXSUSDT-2.76%EOSUSDT-4.24%IMXUSDT-3.36%FARTCOINUSDT-6.86%GALAUSDT-2.38%DYDXUSDT-2.73%ORDIUSDT-2.46%NOTUSDT-2.34%RONINUSDT-2.92%
AB

Arcus Biosciences, Inc. (RCUS)

NYSE • Healthcare

$15.76
-$0.63 (-3.8%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$16.37
Day Range$15.75 - $16.82
Avg. Volume (3M)2.2M
Market Cap$2.2B
52 Week Range
$15.75$31.74

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$9M100%
Gross Profitminus cost of goods$9M100%

Fundamentals & Financials

Revenue (TTM)
$100M
Net Income (TTM)
-$445M
EPS (TTM)
-$3.66
ROA (TTM)
-54.4%
Current Ratio
3.34

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-10.9%Q2 2026-$1.02
+19.2%Q3 2026-$0.72
-12.3%Q4 2026-$1

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -12.3%

Arcus Biosciences trailed consensus on EPS but topped revenue expectations in the third fiscal quarter of 2026, reported November 4, 2026, as revenue fell 65% year over year to about $9.0 million (down from roughly $26.0 million a year ago). On the quarter’s consensus lines, EPS of -$1.00 trailed the -$0.89 estimate by $0.11, while revenue of $9.0 million topped the $7.6 million estimate, +19%. The company, which is advancing immuno-oncology and targeted oncology programs including etrumadenant, zimberelimab, domvanalimab, quemliclustat, and AB521, posted an operating loss of roughly $131.0 million alongside a net loss of about $128.0 million; net income improved 5% year over year from around -$135.0 million. Versus last year, EPS improved 21% from -$1.27. For the next period, consensus calls for EPS of -$0.86 on revenue of $5.5 million.

View full earnings history

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc. (NYSE: RCUS) is a clinical-stage biopharmaceutical company in biotechnology that discovers and aims to commercialize cancer therapies. In FY2025, the company recorded $247.0 million in revenue. Its drug portfolio centers on immuno-oncology and targeted treatment candidates for solid tumors and genetically defined disease.

Name
Arcus Biosciences, Inc.
CEO
Terry J. Rosen
Industry
Healthcare
Year Founded
2015
Employees
601

Today's Snapshot

AI-generated

RCUS closed 3.8% lower on heavier trading than usual.

Trading Volume

Above 10d avg 1.3M

1.9M

vs S&P 500 Today

Strong Underperformance

-3.58%

Updated: November 18, 2026 at 21:26 UTC

Technical Indicators

2 Buy0 Neutral6 Sell
RCUS exhibits pronounced downside characteristics with a strong negative trend and confirming momentum weakness. ADX is elevated, indicating a firm downward trend, while MACD and CCI are negative and momentum has been weakening; short-term oscillators are deeply oversold but have not yet reversed the larger picture. The current price is well below short-, medium- and long-term moving averages and sits beneath the pivot, underscoring resistance overhead. Volatility is relatively high for the share price and on-balance volume is negative, signaling distribution. Technical takeaway: strong-sell bias driven by trend strength, negative momentum, and volume confirmation.
All signals
  • EMA (5 indicators)$17.42 - $23.40
    Sell
  • RSI (14)28.99
    Buy
  • Stochastic %K (14, 3, 3)1.85
    Buy
  • MACD Level (12, 26)-1.52
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.